AEterna Zentaris Inc. Daily Stock Analysis

Daily Stock Analysis, AEZS, AEterna Zentaris Inc, priceseries

AEterna Zentaris Inc. Daily Stock Analysis
Stock Information
Open
0.34
Close
0.33
High
0.34
Low
0.32
Previous Close
0.35
Daily Price Gain
-0.02
YTD High
0.44
YTD High Date
Feb 10, 2022
YTD Low
0.29
YTD Low Date
Jan 24, 2022
YTD Price Change
-0.06
YTD Gain
-14.87%
52 Week High
1.74
52 Week High Date
Mar 15, 2021
52 Week Low
0.29
52 Week Low Date
Jan 24, 2022
52 Week Price Change
-0.73
52 Week Gain
-68.68%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 9. 2017
2.95
Feb 21. 2017
3.19
7 Trading Days
8.02%
Link
LONG
May 25. 2017
0.96
Jun 12. 2017
1.06
11 Trading Days
10.03%
Link
LONG
Jul 19. 2017
2.34
Jul 24. 2017
2.54
3 Trading Days
8.33%
Link
LONG
May 23. 2018
1.94
Jun 5. 2018
2.16
8 Trading Days
11.38%
Link
LONG
Nov 8. 2018
2.13
Nov 23. 2018
2.61
10 Trading Days
22.53%
Link
LONG
Nov 26. 2018
3.00
Dec 11. 2018
3.31
10 Trading Days
10.50%
Link
LONG
Jan 3. 2019
3.08
Jan 18. 2019
3.60
11 Trading Days
16.99%
Link
LONG
Jan 25. 2019
3.63
Feb 13. 2019
3.97
13 Trading Days
9.30%
Link
LONG
Mar 29. 2019
4.65
Apr 11. 2019
4.95
9 Trading Days
6.53%
Link
LONG
Jan 3. 2020
0.88
Jan 27. 2020
1.15
15 Trading Days
30.82%
Link
LONG
Feb 4. 2021
1.08
Feb 17. 2021
1.55
8 Trading Days
43.52%
Link
Company Information
Stock Symbol
AEZS
Exchange
NasdaqCM
Company URL
http://www.aezsinc.com
Company Phone
843-900-3201
CEO
David A. Dodd
Headquarters
Quebec
Business Address
C/O NORTON ROSE FULBRIGHT CANADA LLP, 1 PLACE VILLE MARIE, SUITE 2500, MONTREAL, CANADA H3B 1R1
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001113423
About

Æterna Zentaris, Inc. operates as a specialty biopharmaceutical company that is engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health. The company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. It focuses on the development of Perifosine, Cetrotide, Ozarelix, AEZS-108 and AEZS-130. AEterna Zentaris was founded on September 12, 1990 and is headquartered in Montreal, Canada.

Description

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. The company's product pipeline includes Zoptrex, which is in Phase III clinical study zoptarelin doxorubicin in endometrial cancer (ZoptEC) of the compound in women with advanced, recurrent, or metastatic endometrial cancer, as well as completed Phase II clinical trial for the treatment of ovarian and prostate cancer; and MACRILEN, which is in Phase III trial for use in the diagnosis of adult growth hormone deficiency. It is also developing two oncology compounds, including an Erk inhibitor and luteinizing hormone-releasing hormone-disorazol Z product candidates, which are in pre-clinical development; and AEZS-120 for the treatment of prostate cancer. Aeterna Zentaris Inc. was founded in 1991 and is headquartered in Summerville, South Carolina.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading